This data suggests there is need for further investigation of the role for concurrent treatment with PD-1 inhibitors and GKRS to enhance the treatment of metastatic melanoma. Future studies focusing on the ideal timing for treatment of these two modalities will provide more information regarding their effects. Here, PDCD1 is linked to metastatic melanoma.